Case report tracks urinary ADEV GluN1 levels in anti-NMDAR encephalitis patient during treatment
This case report analyzed a single female patient with anti-NMDAR encephalitis and one healthy female control. The patient received unspecified treatment including methotrexate infusions, with follow-up over 34 days. The study examined whether urinary astrocyte-derived extracellular vesicles (ADEVs) could serve as a non-invasive proxy for brain receptor dynamics.
Wavelet transform analysis of urinary ADEV GluN1 protein levels revealed two patterns: a low-frequency trend of declining GluN1 levels over the treatment period, mirroring reduction in CSF GluN1 concentrations, and a high-frequency oscillation coupled with methotrexate infusions, with GluN1 peaks occurring approximately 48 hours after each dose. No effect sizes, absolute numbers, or statistical analyses were reported. Safety and tolerability data were not reported.
The primary limitation is that this is a single patient case report, severely limiting generalizability. No statistical validation was performed. The authors suggest urinary ADEVs may provide a feasible method to monitor real-time molecular fluxes, but this remains speculative. The observed secondary increase after methotrexate may reflect drug-induced p53 activation, but this mechanism is speculative. Clinical utility cannot be assessed from this single case.